Lumbrokinase vs Serrapeptase: Key Differences for Supplement Ingredient Buyers
Lumbrokinase and serrapeptase differ in biological source, enzyme identity and the activity measurements used to characterize them. Lumbrokinase refers to a group of earthworm-derived fibrinolytic enzymes. Serrapeptase, also called serratiopeptidase, is a bacterial proteolytic enzyme. Both break down protein substrates, but they are not interchangeable ingredients, and their activity numbers do not establish relative clinical effectiveness.
For supplement brands, contract manufacturers and technical teams, the useful comparison concerns which documented material fits the intended product concept. That decision requires source identification, assay review, an evidence assessment and formulation testing—not a ranking based on whichever specification displays the larger number.
Biological Source and Enzyme Identity
What is lumbrokinase?
Lumbrokinase is a collective term for fibrinolytic enzymes obtained from earthworms. Research has characterized multiple enzyme fractions from species including Lumbricus rubellus and Eisenia fetida. A foundational study by Mihara and colleagues isolated several fibrinolytic fractions and introduced the collective name lumbrokinase.PubMed
The term therefore does not identify one universally identical molecule or commercial powder. Species, extraction and downstream processing can influence the preparation being evaluated. Findings from a purified research fraction should not automatically describe every earthworm-derived ingredient.
The What Is Lumbrokinase? Source, Activity and B2B Supply Guide provides the broader ingredient definition. For this comparison, the important point is that earthworm origin and fibrinolytic activity must both connect to the actual supplied material.
What is serrapeptase?
Serrapeptase is a protease associated with Serratia bacteria. It belongs to the serralysin family of metalloproteases, whose catalytic activity involves a metal ion. Experimental production research has purified and characterized serratiopeptidase from bacterial culture.pmc.ncbi.nlm.nih.gov
Descriptions linking serrapeptase to silkworms refer to its historical association with bacteria found in the silkworm environment or digestive tract. Describing it simply as an enzyme extracted from silkworms obscures the microbial source. Buyers should establish the production organism, manufacturing route and composition of the commercial preparation.
“Natural” does not resolve these differences or establish suitability. The Is Lumbrokinase a Natural Enzyme? article addresses that broader origin question; source terminology should remain separate from evidence of performance.
Fibrinolytic and Proteolytic Activity: Related but Different Descriptions
Proteolytic activity means the breakdown of proteins through cleavage of peptide bonds. Fibrinolytic activity concerns breakdown of fibrin, the protein network involved in clot structure. Fibrinolysis is therefore a particular protein-degradation activity, rather than the opposite of proteolysis.
Lumbrokinase research emphasizes fibrin-related activity. Mihara and colleagues demonstrated activity on both plasminogen-rich and plasminogen-free fibrin plates, supporting direct fibrin degradation in the tested preparation. This does not mean that every commercial preparation has an identical enzyme profile or mechanism.PubMed
Serrapeptase is generally characterized as a proteolytic enzyme, with experimental activity measured against defined protein substrates. A protease result obtained with casein, for example, answers a different analytical question from a fibrin-plate result.pmc.ncbi.nlm.nih.gov
Neither description demonstrates what an orally consumed finished supplement will do in humans. Substrate breakdown in a laboratory does not establish absorption, delivery to a biological target, clinical benefit or comparative safety.
Lumbrokinase vs Serrapeptase Comparison Table
| Evaluation factor | Lumbrokinase | Serrapeptase |
|---|---|---|
| Enzyme identity | Group of earthworm-derived fibrinolytic enzymes; preparation composition can vary | Serratiopeptidase, a bacterial metalloprotease; commercial preparations require identity confirmation |
| Biological source | Earthworms; verify declared species and traceability | Microbial production associated with Serratia; verify organism and manufacturing route |
| General biochemical activity | Fibrin degradation under defined experimental conditions | Proteolysis against specified protein substrates |
| Activity testing context | Fibrin-based assays are relevant; Allworms uses Fibrin Plate Assay | Review the supplier’s actual protease method, substrate and unit definition |
| Specification evaluation | Allworms: fibrinolytic activity ≥500,000 U/g; assess alongside method and batch COA | Obtain the offered grade’s specification and batch result; no universal value is assumed here |
| Formulation considerations | Evaluate activity retention in the proposed matrix, process and packaging | Evaluate activity retention in the proposed matrix, process and packaging |
| Evidence limitations | Research preparations and clinical products do not automatically represent commercial powders | Laboratory and clinical findings do not validate every supplement preparation or claim |
| B2B purchasing considerations | Confirm source, composition, assay details and batch documentation | Confirm microbial origin, composition, assay details and batch documentation |
| Direct comparison boundary | Activity figures cannot establish a potency ratio against serrapeptase | Activity figures cannot establish clinical equivalence to lumbrokinase |
What Does Published Research Establish?
Separate laboratory, animal and human evidence
In vitro studies can identify enzymes, characterize substrate activity and investigate mechanisms. Animal studies can explore biological responses in a living system, but differences in species, administration and experimental design limit direct translation to humans.
Human clinical studies answer narrower questions about the tested preparation, population, treatment setting and outcomes. Commercial supplement claims require a separate assessment of whether that evidence applies to the finished product. These evidence categories should not be combined into one general statement that an ingredient is “clinically proven.”
Lumbrokinase research is preparation-specific
A 2013 randomized controlled study investigated enteric-coated lumbrokinase alongside standard care in people with previous ischemic stroke. This is research in a medical setting, not validation of an Allworms powder or a general supplement claim.PubMed
A separate 2021 randomized, open-label study evaluated DLBS1033, a particular earthworm-derived protein fraction, as an addition to standard treatment. Its design and material identity matter when assessing applicability. Neither study establishes that all earthworm enzyme preparations are clinically equivalent.PubMed
Serrapeptase clinical findings are not uniform
A 2021 randomized dental-surgery trial reported improvements in some swelling and mouth-opening outcomes, without a significant difference in reported pain. An earlier 2009 trial using a dental impaction model did not find significant analgesic or anti-inflammatory action for serratiopeptidase.PubMed
These studies involved specific short-term postoperative settings. They do not justify broad supplement efficacy claims or a conclusion that serrapeptase is superior or inferior to lumbrokinase. Comparing outcomes from unrelated trials would also confound differences in participants, formulations and study methods.
Why Enzyme Activity Values Cannot Be Ranked Directly
An enzyme activity value describes performance in a defined analytical system. Its meaning depends on the substrate, reference material, reaction conditions, calculation and reporting basis. The unit symbol alone does not supply that information.
For current Allworms commercial information:
- Fibrinolytic Activity: 10,000 IU/mg
- Assay Method: Fibrin Plate Assay
This is a specification for activity measured using the stated method. It is not a clinical-effectiveness score, a purity percentage or a conversion reference for serrapeptase.
Do not directly convert U/g, IU/mg, FU/g, LKU or serrapeptase activity units into one another without validated, method-specific evidence. Even two reports using “U” may measure different reactions. Changing a mass denominator cannot make different assay definitions equivalent.
Before commissioning comparative testing, provide the laboratory with both methods and ask what question a parallel experiment can legitimately answer. Testing both materials under one protocol might compare a particular substrate response; it would not establish overall biochemical interchangeability or clinical superiority.
For detailed reporting guidance, see Lumbrokinase Activity Units: IU/mg, FU/g, LKU and U Explained.
Practical Considerations for Supplement Formulation
Begin with the supplied raw material. Establish whether it is a concentrated enzyme preparation, a standardized blend, a carrier-containing powder or a coated material. Record declared excipients and the basis on which activity is reported. Ingredient weight alone does not reveal enzyme composition or retained activity.
Next, assess the proposed formula and process. Temperature, moisture, pH exposure and contact with other ingredients should be considered in development testing. Determine activity before and after relevant processing steps, using an appropriate method that works in the finished-product matrix.
Request stability information for the offered grade and packaging. Separate storage data for raw powder from evidence for a completed capsule, tablet or blend. A shelf-life statement for one material does not establish stability in a different formulation. Likewise, a coated format should not be assumed to deliver a particular gastrointestinal performance without supporting tests.
Documentation should include a specification, batch COA, identity and source information, assay details, composition and available stability records. Review microbiological and contaminant controls against the buyer’s requirements. Where documents are missing, identify the evaluation gap rather than substituting general research literature.
Choosing an Ingredient for Further Evaluation
Define the intended product concept before selecting an enzyme. If the concept specifically requires a documented earthworm-derived fibrinolytic ingredient, lumbrokinase is the relevant candidate category. If it requires serratiopeptidase, an earthworm preparation is not an identity-equivalent substitute.
Then assess market suitability with the responsible regulatory team. An ingredient’s availability elsewhere does not establish acceptance, labeling suitability or permissible claims in the United States, Europe, Australia or Canada.
Advance the candidate only when its documentation and preliminary tests support the project’s requirements. Buyers considering another enzyme pairing can consult Lumbrokinase vs Nattokinase: Key Differences for B2B Ingredient Buyers as a separate comparison.
Frequently Asked Questions
Is lumbrokinase the same as serrapeptase?
No. Lumbrokinase describes earthworm-derived fibrinolytic enzymes; serrapeptase is bacterial serratiopeptidase. Their identities and analytical specifications differ.
Does a higher activity number mean a stronger ingredient?
Only a compatible, validated comparison can support a defined analytical conclusion. Numbers from different substrates or unit systems cannot rank overall strength or human effectiveness.
Can lumbrokinase and serrapeptase be used together?
A combination requires its own regulatory, safety, compatibility and stability assessment. Separate ingredient data do not demonstrate synergy or validate the finished blend.
Review the current specification with our Lumbrokinase Powder Supplier team. Discuss your ingredient evaluation requirements with Allworms.